3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Genitourinary
1
Breast
1
Conditions
Neoplasms
14
Venous Thromboembolism
11
Venous Thrombosis
4
Thrombosis
3
Pulmonary Embolism
3
Multiple Myeloma
3
Upper Extremity Deep Vein Thrombosis
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thromboembolism
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Prevention of Venous Thromboembolism
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia
1
Inflammation
1
Immune System Diseases
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Interventions
Sorafenib
131
lenvatinib
115
Bevacizumab
88
Radiosurgery
69
atezolizumab
55
sintilimab
54
Nivolumab
51
durvalumab
43
Hepatectomy
43
Fluorouracil
42
apatinib
41
Oxaliplatin
41
camrelizumab
38
Radiofrequency Ablation
38
pembrolizumab
36
Radiotherapy
36
tislelizumab
35
Leucovorin
31
Magnetic Resonance Spectroscopy
30
Immune Checkpoint Inhibitors
28
Doxorubicin
28
Folfox protocol
26
tremelimumab
25
regorafenib
25
Cisplatin
20
spartalizumab
19
donafenib
19
Gemcitabine
19
Cyclophosphamide
19
toripalimab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Hepatocellular
×
Rivaroxaban
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled